Fig. 1. Effects of CF administration on prostate weights in TP-induced BPH rats.
Fig. 2. Effects of CF administration on the histological changes in the prostate tissues and DHT in serum of TP-induced BPH rats.
Fig. 3. Effects of CF administration on 5α-reductase type 2 in TP-induced BPH rats.
Fig. 4. Effects of CF administration on the expression of AR, SRC1, PCNA and cyclins in TP-induced BPH rats.
Fig. 5. Effects of CF administration on PSA in TP-induced BPH rats.
Table 1. Classification of experiment groups
Table 2. Effects of CF treatment on the several organ weights of TP-induced BHP rats
Table 3. Effects of CF treatment on the serum biochemical parameters for the liver and kidney functions of TP-induced BHP rats
References
- Aaron, L., Franco, O. E. and Hayward, S. W. 2016. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Urol. Clin. North. Am. 43, 279-288. https://doi.org/10.1016/j.ucl.2016.04.012
- Al-Khalil, S., Boothe, D., Durdin, T., Sunkara, S., Watkins, P., Yang, S., Haynes, A. and de Riese, W. 2016. Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review. Int. Urol. Nephrol. 48, 91-97. https://doi.org/10.1007/s11255-015-1146-2
- Andriole, G., Bruchovsky, N., Chung, L. W., Matsumoto, A. M., Rittmaster, R., Roehrborn, C., Russell, D. and Tindall, D. 2004. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J. Urol. 172, 1399-1403. https://doi.org/10.1097/01.ju.0000139539.94828.29
-
Azzouni, F. and Mohler, J. 2012. Role of 5
${\alpha}$ -reductase inhibitors in benign prostatic diseases. Prostate Cancer Prostatic Dis. 15, 222-230. https://doi.org/10.1038/pcan.2012.1 - Boehm, E. M., Gildenberg, M. S. and Washington, M. T. 2016. The many roles of PCNA in eukaryotic DNA replication. Enzymes 39, 231-254.
- Bostanci, Y., Kazzazi, A., Momtahen, S., Laze, J. and Djavan, B. 2013. Correlation between benign prostatic hyperplasia and inflammation. Curr. Opin. Urol. 23, 5-10. https://doi.org/10.1097/MOU.0b013e32835abd4a
- Botticelli, A. R., Criscuolo, M., Martinelli, A. M., Botticelli, L., Filoni, A. and Migaldi, M. 1993. Proliferating cell nuclear antigen/cyclin in incidental carcinoma of the prostate. Virchows Arch. A Pathol. Anat. Histopathol. 423, 365-368.
- Chang, J. S., Chiang, L. C., Hsu, F. F. and Lin, C. C. 2004. Chemoprevention against hepatocellular carcinoma of Cornus officinalis in vitro. Am. J. Chin. Med. 32, 717-725. https://doi.org/10.1142/S0192415X04002296
- Choe, K. N. and Moldovan, G. L. 2017. Forging ahead through darkness: PCNA, still the principal conductor at the replication Fork. Mol. Cell 65, 380-392. https://doi.org/10.1016/j.molcel.2016.12.020
- Cornu, J. N., Ahyai, S., Bachmann, A., de la Rosette, J., Gilling, P., Gratzke, C., McVary, K., Novara, G., Woo, H. and Madersbacher, S. 2015. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: An update. Eur. Urol. 67, 1066-1096. https://doi.org/10.1016/j.eururo.2014.06.017
- Gharaee-Kermani, M. and Macoska, J. A. 2013. Promising molecular targets and biomarkers for male BPH and LUTS. Curr. Urol. Rep. 14, 628-637. https://doi.org/10.1007/s11934-013-0368-z
- Ho, C. K. and Habib, F. K. 2011. Estrogen and androgen signaling in the pathogenesis of BPH. Nat. Rev. Urol. 8, 29-41. https://doi.org/10.1038/nrurol.2010.207
- Huang, J., Zhang, Y., Dong, L., Gao, Q., Yin, L., Quan, H., Chen, R., Fu, X. and Lin, D. 2018. Ethnopharmacology, phytochemistry, and pharmacology of Cornus officinalis Sieb. et Zucc. J. Ethnopharmacol. 213, 280-301. https://doi.org/10.1016/j.jep.2017.11.010
- Hwang, K. A., Hwang, Y. J. and Song, J. 2016. Antioxidant activities and oxidative stress inhibitory effects of ethanol extracts from Cornus officinalis on raw 264.7 cells. BMC Complement. Altern. Med. 16, 196. https://doi.org/10.1186/s12906-016-1172-3
- Jeong, E. J., Kim, T. B., Yang, H., Kang, S. Y., Kim, S. Y., Sung, S. H. and Kim, Y. C. 2012. Neuroprotective iridoid glycosides from Cornus officinalis fruits against glutamateinduced toxicity in HT22 hippocampal cells. Phytomedicine 19, 317-321. https://doi.org/10.1016/j.phymed.2011.08.068
- Jiang, W. L., Chen, X. G., Zhu, H. B., Hou, J. and Tian, J. W. 2009. Cornuside attenuates apoptosis and ameliorates mitochondrial energy metabolism in rat cortical neurons. Pharmacology 84, 162-170. https://doi.org/10.1159/000235621
- Kang, D. G., Moon, M. K., Lee, A. S., Kwon, T. O., Kim, J. S. and Lee, H. S. 2007. Cornuside suppresses cytokine-induced proinflammatory and adhesion molecules in the human umbilical vein endothelial cells. Biol. Pharm. Bull. 30, 1796-1799. https://doi.org/10.1248/bpb.30.1796
- Keam, S. J. and Scott, L. J. 2008. Dutasteride: a review of its use in the management of prostate disorders. Drugs 68, 463-485. https://doi.org/10.2165/00003495-200868040-00008
- Lepor, H. 2016. Alpha-blockers for the treatment of benign prostatic hyperplasia. Urol. Clin. North. Am. 43, 311-323. https://doi.org/10.1016/j.ucl.2016.04.009
- Ma, W., Wang, K. J., Cheng, C. S., Yan, G. Q., Lu, W. L., Ge, J. F., Cheng, Y. X. and Li, N. 2014. Bioactive compounds from Cornus officinalis fruits and their effects on diabetic nephropathy. J. Ethnopharmacol. 153, 840-845. https://doi.org/10.1016/j.jep.2014.03.051
- Minciullo, P. L., Inferrera, A., Navarra, M., Calapai, G., Magno, C. and Gangemi, S. 2015. Oxidative stress in benign prostatic hyperplasia: a systematic review. Urol. Int. 94, 249-254. https://doi.org/10.1159/000366210
- Nakayama, Y. and Yamaguchi, N. 2013. Role of cyclin B1 levels in DNA damage and DNA damage-induced senescence. Int. Rev. Cell. Mol. Biol. 305, 303-337.
- Nemoto, R., Kawamura, H., Miyakawa, I., Uchida, K., Hattori, K., Koiso, K. and Harada, M. 1993. Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma. J. Urol. 149, 165-169. https://doi.org/10.1016/S0022-5347(17)36031-7
- Nicholson, T. M. and Ricke, W. A. 2011. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82, 184-199. https://doi.org/10.1016/j.diff.2011.04.006
- Park, J. Y., Han, A. R., Kil, Y. S., Kang, U., Kim, S. H., Nam, S. J. and Seo, E. K. 2016. A new secoiridoid glycoside from the fruits of Cornus officinalis (Cornaceae). Nat. Prod. Res. 30, 1504-1510. https://doi.org/10.1080/14786419.2015.1115996
- Pihlajamaa, P., Sahu, B. and Janne, O. A. 2015. Determinants of receptor- and tissue-specific actions in androgen signaling. Endocr. Rev. 36, 357-384. https://doi.org/10.1210/er.2015-1034
- Pomerantz, Y. and Dekel, N. 2013. Molecular participants in regulation of the meiotic cell cycle in mammalian oocytes. Reprod. Fertil. Dev. 25, 484-494. https://doi.org/10.1071/RD12242
- Prins, G. S. 2000. Molecular biology of the androgen receptor. Mayo Clin. Proc. 75, S32-35.
- Pyo, J. S. and Cho, W. J. 2017. Systematic review and metaanalysis of prostatic artery embolisation for lower urinary tract symptoms related to benign prostatic hyperplasia. Clin. Radiol. 72, 16-22. https://doi.org/10.1016/j.crad.2016.10.009
- Robins, D. M. 2005. Androgen receptor and molecular mechanisms of male-specific gene expression. Novartis Found. Symp. 268, 42-52.
- Romero Otero, J., Garcia Gomez, B., Campos Juanatey, F. and Touijer, K. A. 2014. Prostate cancer biomarkers: an update. Urol. Oncol. 32, 252-260. https://doi.org/10.1016/j.urolonc.2013.09.017
- Seo, J. Y., Pyo, E., Park, J., Kim, J. S., Sung, S. H. and Oh, W. K. 2017. Nrf2-mediated HO-1 induction and antineuroinflammatory activities of halleridone. J. Med. Food 20, 1091-1099. https://doi.org/10.1089/jmf.2017.3949
- Smith, R. D. and Patel, A. 2011. Transurethral resection of the prostate revisited and updated. Curr. Opin. Urol. 21, 36-41. https://doi.org/10.1097/MOU.0b013e3283411455
- Steers, W. D. 2001. 5alpha-reductase activity in the prostate. Urology 58, S17-24. https://doi.org/10.1016/S0090-4295(01)01299-7
- Strand, D. W., Costa, D. N., Francis, F., Ricke, W. A. and Roehrborn, C. G. 2017. Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Differentiation 96, 49-61. https://doi.org/10.1016/j.diff.2017.07.005
- Telang, N. T., Li, G., Sepkovic, D. W., Bradlow, H. L. and Wong, G. Y. 2012. Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor-positive clinical breast cancer. Mol. Med. Rep. 5, 22-28.
- Thorner, D. A. and Weiss, J. P. 2009. Benign prostatic hyperplasia: symptoms, symptom scores, and outcome measures. Urol. Clin. North. Am. 36, 417-429. https://doi.org/10.1016/j.ucl.2009.07.001
-
Traish, A. M., Melcangi, R. C., Bortolato, M., Garcia-Segura, L. M. and Zitzmann, M. 2015. Adverse effects of 5
${\alpha}$ -reductase inhibitors: What do we know, don't know, and need to know? Rev. Endocr. Metab. Disord. 16, 177-198. https://doi.org/10.1007/s11154-015-9319-y -
Traish, A. M. 2012.
$5{\alpha}$ -reductases in human physiology: an unfolding story. Endocr. Pract. 18, 965-975. https://doi.org/10.4158/EP12108.RA - Van Coppenolle, F., Le Bourhis, X., Carpentier, F., Delaby, G., Cousse, H., Raynaud, J. P., Dupouy, J. P. and Prevarskaya, N. 2000. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. Prostate 43, 49-58. https://doi.org/10.1002/(SICI)1097-0045(20000401)43:1<49::AID-PROS7>3.0.CO;2-J
- Vignozzi, L., Rastrelli, G., Corona, G., Gacci, M., Forti, G. and Maggi, M. 2014. Benign prostatic hyperplasia: a new metabolic disease? J. Endocrinol. Invest. 37, 313-322. https://doi.org/10.1007/s40618-014-0051-3
-
Yoon, J. H., Youn, K., Ho, C. T., Karwe, M. V., Jeong, W. S. and Jun, M. 2014. p-Coumaric acid and ursolic acid from Corni fructus attenuated
${\beta}$ -amyloid(25-35)-induced toxicity through regulation of the NF-${\kappa}B$ signaling pathway in PC12 cells. J. Agric. Food Chem. 62, 4911-4916. https://doi.org/10.1021/jf501314g